Impact of COVID-19 on Canadian Medical Oncologists and Cancer Care: Canadian Association of Medical Oncologists Survey Report

Abstract


 Background The covid-19 pandemic has presented unprecedented professional and personal challenges for the oncology community. Under the auspices of the Canadian Association of Medical Oncologists, we conducted an online national survey to better understand the impact of the pandemic on the medical oncology community in Canada.
 Methods An English-language multiple-choice survey, including questions about demographics, covid-19 risk, use of personal protective equipment (ppe), personal challenges, and chemotherapy management was distributed to Canadian medical oncologists. The survey was open from 30 March to 4 April 2020, and attracted 159 responses.
 Results More than 70% of medical oncologists expressed moderate-to-extreme concern about personally contracting covid-19 and about family members or patients (or both) contracting covid-19 from them. Despite that high level of concern, considerable variability in the use of ppe in direct cancer care was reported at the time of this survey, with 33% of respondents indicating no routine ppe use at their institutions and 69% indicating uncertainty about access to adequate ppe. Of the respondents, 54% were experiencing feelings of nervousness or anxiety on most days, and 52% were having feelings of depression or hopelessness on at least some days. Concern about aging parents or family and individual wellness represented the top personal challenges identified. The management of cancer patients has been affected, with adoption of telemedicine reported by 82% of respondents, and cessation of clinical trial accrual reported by 54%. The 3 factors deemed most important for treatment decision-making were
 
 cancer prognosis and anticipated benefit from treatment,
 risk of treatment toxicity during scarce health care access, and
 patient risk of contracting covid-19.
 
 Conclusions This report describes the results of the first national survey assessing the impact of the covid-19 on Canadian medical oncologists and how they deliver systemic anticancer therapies. We hope that these data will provide a framework to address the challenges identified.

Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

“…Regarding everolimus and sunitinib, to date there is no available scientific data to compare this figure with other reports even outside the setting of NEN patients. As far as chemotherapy is concerned, other surveys performed of nonendocrine cancers have reported a low proportion of oncologists who changed treatment plans in their clinical practice [19,20]. This figure is in agreement with data reported by the present survey, confirming the ability of the NEN dedicated teams to continue to provide optimal care to their patients.…”

Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives

“…In assessing care patterns and patient perspectives, we found that nearly two-thirds of study participants reported having a virtual oncology appointment during the first wave of the COVID-19 pandemic. This corroborates findings of a recent survey of Canadian medical oncologists that reported 82% used some form of virtual care [ 6 ]. Furthermore, our finding that the majority of patients (83%) were satisfied with their virtual oncology appointments provides reassurance to healthcare providers.…”

Experiences and management of physician psychological symptoms during infectious disease outbreaks: a rapid review

“…The most common psychological symptoms measured with surveys or validated questionnaires reported included anxiety ( n = 103), depression ( n = 73), stress ( n = 68), fear ( n = 61), burnout ( n = 25), mental distress/health ( n = 21), and post-traumatic stress disorder (PTSD) ( n = 14) (Additional File 3 ). Most COVID-19 studies reported on physicians from USA ( n = 23) [ 41 , 52 , 66 , 70 , 77 , 90 – 107 ], China ( n = 22) [ 15 , 49 , 54 – 56 , 65 , 68 , 73 , 86 , 89 , 102 , 108 – 118 ] followed by India ( n = 21) [ 40 , 50 , 58 , 63 , 67 , 71 , 102 , 119 – 132 ] [ 41 , 52 , 66 , 70 , 77 ], Italy ( n = 10) [ 32 , 94 , 102 , 125 , 133 – 138 ], and Turkey ( n = 11) [ 35 , 44 , 94 , 139 – 146 ] [ 28 , 30 , 32 , 34 , 36 , 37 , 42 , 45 , 47 , 48 , 59 , 60 , 62 , 80 , 87 ]. .Sixtee...…”